XORTX THERAPEUTICS INC reports a Return on Equity (ROE) of -214.76%.

What is XRTX's dividend yield?

XORTX THERAPEUTICS INC offers a dividend yield of 0.00%.

What is XRTX's Quality Score?

Our AI rates XRTX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy XRTX?

Our AI Timing Score for XRTX is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does XRTX belong to?

XORTX THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

XRTX (NASDAQ) Stock Analysis | XORTX THERAPEUTICS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

XRTX AI Analysis Summary

Our AI summary for XRTX: XORTX THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -214.76%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

XRTX

XORTX THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 2.12

0.10 (4.95%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-214.8%

ROE

-128.6%

ROA

0.00%

Div Yield

XORTX THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.12 Price 0.10 (4.95%) Day Change	NEWS SCORE: 98

XRTX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.12
PBV / Sector	2.71 / 5.20
Earning Per Share	-1.68

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	0.03 M GREAT
Average 1W Daily Value	0.03 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-128.55 / 27.02
ROA Average (%) / Sector	-82.71 / -368.17
ROA Change Average (%) / Sector	24.57 / 5,404.12 GREAT
ROE (%) / Sector	-214.76 / 3.47
ROE Average (%) / Sector	-119.70 / 6.51
ROE Change Average (%) / Sector	29.60 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:43
Symbol	XRTX
Name	XORTX THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	1.73 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	3.50 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3710 - 33rd Street NW, Calgary, AB, Canada, T2L 2M1

Phone: 403-455-7727

Website: https://www.xortx.com

Sector: Healthcare >> Biotechnology

Description: XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.